• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

失代偿期肝硬化患者腹水并发症的危险因素:逻辑回归与预测模型

Ascites complications risk factors of decompensated cirrhosis patients: logistic regression and prediction model.

作者信息

Zheng Xiaolong, Wei Wei

机构信息

The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.

出版信息

BMC Gastroenterol. 2025 May 22;25(1):397. doi: 10.1186/s12876-025-04002-x.

DOI:10.1186/s12876-025-04002-x
PMID:40405077
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12100819/
Abstract

OBJECTIVE

The study mainly aim at exploring the ascites risk factors among decompensated cirrhosis patients via constructing the prediction model of ascites incidence.

METHODS

Here, we recruited 148 decompensated cirrhosis patients for analysis, their laboratory tests and complications recorded. T-test, chi-square test, single-factor logistic regression, multi-factor logistic regression, and nomogram model were used to investigate the ascites occurred factors in decompensated cirrhosis patients with ascites. To validate the data analysis results, we applied the receiver operating characteristic (ROC) curve, calibration curve, and decision curve analysis (DCA) to evaluate the discrimination, calibration, and clinical usefulness of the prediction model, respectively.

RESULTS

Serum creatinine levels were higher in the cirrhotic ascites group than in the non-ascites group. The ascites group had lower albumin and serum sodium levels, as well as a lower incidence of variceal bleeding and varicose veins compared to the non-ascites group.

CONCLUSION

Varicose veins, variceal bleeding, and serum sodium levels are significant factors contributing to ascites development in cirrhosis. Furthermore, decreased serum albumin and elevated creatinine levels are important indicators of poor prognosis. Nomograms can improve clinicians' informed decision-making for patients with decompensated cirrhosis, ultimately reducing ascites risk.

摘要

目的

本研究主要旨在通过构建腹水发生率预测模型来探索失代偿期肝硬化患者的腹水危险因素。

方法

我们招募了148例失代偿期肝硬化患者进行分析,记录他们的实验室检查和并发症情况。采用t检验、卡方检验、单因素逻辑回归、多因素逻辑回归和列线图模型来研究失代偿期肝硬化腹水患者发生腹水的因素。为验证数据分析结果,我们应用受试者工作特征(ROC)曲线、校准曲线和决策曲线分析(DCA)分别评估预测模型的辨别力、校准度和临床实用性。

结果

肝硬化腹水组的血清肌酐水平高于非腹水组。与非腹水组相比,腹水组的白蛋白和血清钠水平较低,静脉曲张出血和静脉曲张的发生率也较低。

结论

静脉曲张、静脉曲张出血和血清钠水平是肝硬化腹水发生的重要因素。此外,血清白蛋白降低和肌酐水平升高是预后不良的重要指标。列线图可以改善临床医生对失代偿期肝硬化患者的知情决策,最终降低腹水风险。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55b1/12100819/f0fb1b3267ec/12876_2025_4002_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55b1/12100819/f4f8602ef222/12876_2025_4002_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55b1/12100819/51f5dec142d8/12876_2025_4002_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55b1/12100819/b0315b217893/12876_2025_4002_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55b1/12100819/efcc6d0c1aa0/12876_2025_4002_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55b1/12100819/f0fb1b3267ec/12876_2025_4002_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55b1/12100819/f4f8602ef222/12876_2025_4002_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55b1/12100819/51f5dec142d8/12876_2025_4002_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55b1/12100819/b0315b217893/12876_2025_4002_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55b1/12100819/efcc6d0c1aa0/12876_2025_4002_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55b1/12100819/f0fb1b3267ec/12876_2025_4002_Fig5_HTML.jpg

相似文献

1
Ascites complications risk factors of decompensated cirrhosis patients: logistic regression and prediction model.失代偿期肝硬化患者腹水并发症的危险因素:逻辑回归与预测模型
BMC Gastroenterol. 2025 May 22;25(1):397. doi: 10.1186/s12876-025-04002-x.
2
Establishment and validation of a nomogram for predicting esophagogastric variceal bleeding in patients with liver cirrhosis.肝硬化患者食管胃静脉曲张出血预测列线图的建立与验证
World J Gastroenterol. 2025 Mar 7;31(9):102714. doi: 10.3748/wjg.v31.i9.102714.
3
[Risk factors and construction of a nomogram model for cirrhotic portal vein thrombosis combined with esophagogastric variceal bleeding].[肝硬化门静脉血栓形成合并食管胃静脉曲张出血的危险因素及列线图模型构建]
Zhonghua Gan Zang Bing Za Zhi. 2023 Oct 20;31(10):1035-1042. doi: 10.3760/cma.j.cn501113-20220712-00377.
4
Influence of further decompensation on survival across clinical stages of decompensated cirrhosis: The role of portal hypertension and HVPG changes.失代偿期肝硬化各临床分期进一步失代偿对生存的影响:门静脉高压和 HVPG 变化的作用。
Liver Int. 2024 Aug;44(8):1971-1989. doi: 10.1111/liv.15937. Epub 2024 Apr 18.
5
Development and evaluation of a predictive model of upper gastrointestinal bleeding in liver cirrhosis.肝硬化患者上消化道出血预测模型的开发与评估
BMC Gastroenterol. 2025 Mar 6;25(1):142. doi: 10.1186/s12876-025-03677-6.
6
A novel prognostic model for predicting the risk of first variceal hemorrhage in patients with HBV-related cirrhosis.一种用于预测 HBV 相关肝硬化患者首次静脉曲张出血风险的新型预后模型。
Front Cell Infect Microbiol. 2023 Jan 17;13:1062172. doi: 10.3389/fcimb.2023.1062172. eCollection 2023.
7
Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.肝静脉压力梯度可预测代偿期肝硬化患者的临床失代偿情况。
Gastroenterology. 2007 Aug;133(2):481-8. doi: 10.1053/j.gastro.2007.05.024. Epub 2007 May 21.
8
Assessment of nomogram model for the prediction of esophageal variceal hemorrhage in hepatitis B-induced hepatic cirrhosis.乙型肝炎肝硬化食管静脉曲张出血预测列线图模型评估。
Eur J Gastroenterol Hepatol. 2024 Jun 1;36(6):758-765. doi: 10.1097/MEG.0000000000002750. Epub 2024 Apr 24.
9
Computed tomography-based multi-organ radiomics nomogram model for predicting the risk of esophagogastric variceal bleeding in cirrhosis.基于计算机断层扫描的多器官放射组学列线图模型预测肝硬化患者胃食管静脉曲张出血风险。
World J Gastroenterol. 2024 Sep 28;30(36):4044-4056. doi: 10.3748/wjg.v30.i36.4044.
10
Machine Learning-based Development and Validation of a Scoring System for Screening High-Risk Esophageal Varices.基于机器学习的高危食管静脉曲张筛查评分系统的开发和验证。
Clin Gastroenterol Hepatol. 2019 Aug;17(9):1894-1901.e1. doi: 10.1016/j.cgh.2019.01.025. Epub 2019 Jan 29.

本文引用的文献

1
Review article: Recent advances in ascites and acute kidney injury management in cirrhosis.综述文章:肝硬化腹水和急性肾损伤管理的最新进展。
Aliment Pharmacol Ther. 2024 May;59(10):1196-1211. doi: 10.1111/apt.17972. Epub 2024 Mar 25.
2
Prevalence and risk factors of lymphatic dysfunction in cirrhosis patients with refractory ascites: An often unconsidered mechanism.肝硬化难治性腹水患者淋巴功能障碍的患病率及危险因素:一种常被忽视的机制。
World J Hepatol. 2023 Oct 27;15(10):1140-1152. doi: 10.4254/wjh.v15.i10.1140.
3
Albumin administration in internal medicine: A journey between effectiveness and futility.
内科白蛋白治疗:从有效到无效的探索之旅。
Eur J Intern Med. 2023 Nov;117:28-37. doi: 10.1016/j.ejim.2023.07.003. Epub 2023 Jul 7.
4
Soluble Guanylyl Cyclase Activator BI 685509 Reduces Portal Hypertension and Portosystemic Shunting in a Rat Thioacetamide-Induced Cirrhosis Model.可溶性鸟苷酸环化酶激活剂 BI 685509 可降低硫代乙酰胺诱导的大鼠肝硬化模型中的门静脉高压和门体分流。
J Pharmacol Exp Ther. 2023 Jul;386(1):70-79. doi: 10.1124/jpet.122.001532. Epub 2023 May 25.
5
Diagnosis and Management of Cirrhosis and Its Complications: A Review.肝硬化及其并发症的诊断与管理:综述。
JAMA. 2023 May 9;329(18):1589-1602. doi: 10.1001/jama.2023.5997.
6
Hepatorenal syndrome: Current concepts and future perspectives.肝肾综合征:当前概念与未来展望。
Clin Mol Hepatol. 2023 Oct;29(4):891-908. doi: 10.3350/cmh.2023.0024. Epub 2023 Apr 13.
7
Global epidemiology of cirrhosis - aetiology, trends and predictions.全球肝硬化的流行病学:病因、趋势和预测。
Nat Rev Gastroenterol Hepatol. 2023 Jun;20(6):388-398. doi: 10.1038/s41575-023-00759-2. Epub 2023 Mar 28.
8
Acute Kidney Injury in Patients with Cirrhosis.肝硬化患者的急性肾损伤
N Engl J Med. 2023 Feb 23;388(8):733-745. doi: 10.1056/NEJMra2215289.
9
Long-term albumin treatment in patients with cirrhosis and ascites.肝硬化伴腹水患者的长期白蛋白治疗。
J Hepatol. 2022 Jun;76(6):1306-1317. doi: 10.1016/j.jhep.2022.03.005.
10
Chronic liver diseases must be reduced worldwide: it is time to act.全球范围内必须减少慢性肝病:是时候采取行动了。
Lancet Glob Health. 2022 Apr;10(4):e471-e472. doi: 10.1016/S2214-109X(22)00047-X.